Tumor Ablation Market Research, 2032
The global tumor ablation market size was valued at $1.4 billion in 2022, and is projected to reach $5 billion by 2032, growing at a CAGR of 13.5% from 2022 to 2032. The rise in prevalence of cancer, and surge in adoption of tumor ablation devices by healthcare professionals are the major factors that propel the growth of the market. For instance, according to American Cancer Society, in 2022, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S. Furthermore, according to 2023 report by Cancer Research UK, the incidence rates of cancer has increased by 12% from early 1990s to 2023.
Key Takeaways:
By technology, the others segment was the highest contributor to the market in 2022.
By treatment, the surgical ablation segment was the highest contributor to the market in 2022.
By application, the liver cancer segment dominated the market in 2022, and is expected to continue this trend during the forecast period.
By region, North America garnered the largest revenue share in 2022. However, Asia-Pacific is expected to grow at the fastest rate during the forecast period
Tumor ablation devices are innovative medical tools and techniques used in the treatment of tumors, particularly in cases where surgery is not a viable option or when patients seek minimally invasive alternatives. These devices work by destroying cancerous or benign tumors, often through localized heat or freezing methods. Radiofrequency ablation (RFA) and microwave ablation (MWA) devices employ high-frequency electromagnetic waves to generate heat, effectively cooking and destroying tumor cells. Cryoablation devices, on the other hand, use extremely cold temperatures to freeze and eradicate the tumor.
Market Dynamics
The tumor ablation market share is expected to grow significantly, owing to surge in prevalence cancer and rise in demand of minimally invasive approach for tumor removal. The rise in the prevalence of cancer has emerged as a major driver for the tumor ablation market, reflecting a growing global healthcare concern. Cancer has become a formidable global health challenge, with an increasing number of individuals diagnosed each year. For instance, according to Pan American Health Organization, it was estimated that by 2040, the global burden of cancer will increase to about 30 million new cancer cases. As the incidence of cancer continues to grow, there is an escalating demand for innovative and effective treatment options.
Tumor ablation techniques have gained prominence as a minimally invasive approach to combat cancer, often as an alternative or adjunct to traditional therapies like surgery, chemotherapy, or radiation. Ablation methods, including radiofrequency, microwave, and cryoablation, offer precision and reduced side effects, making them an appealing choice for both patients and clinicians. With advances in ablation technologies, such as radiofrequency ablation, microwave ablation, and cryoablation, more cancer patients are benefiting from these treatments. In conclusion, the rise in cancer prevalence has become a pivotal factor propelling the tumor ablation market growth.
The high adoption of minimally invasive technology has emerged as a major driving force behind the exponential growth of the tumor ablation market size in recent years. Minimally invasive procedures, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have revolutionized the treatment of various types of tumors, including those in the liver, lung, kidney, and prostate. These techniques offer several compelling advantages, which have resonated with both patients and healthcare providers alike.
One of the primary factors contributing to the surge in minimally invasive procedures is the reduced morbidity associated with these treatments. Unlike traditional open surgeries, minimally invasive ablation techniques require only small incisions, resulting in less pain, shorter hospital stays, and quicker recovery times. This not only enhances the overall patient experience but also significantly reduces healthcare costs, making it an attractive option for both patients and healthcare systems.
Additionally, the high adoption of minimally invasive tumor ablation techniques can be attributed to their effectiveness in treating a wide range of tumors, including those located in challenging or inaccessible areas of the body. These procedures have become a go-to option for patients who may not be suitable candidates for traditional open surgery. The increasing prevalence of cancer, coupled with an aging population, has further fueled the demand for minimally invasive tumor ablation techniques as they offer a less invasive and more convenient alternative to surgery, particularly for elderly or frail patients. Thus, high adoption of minimally invasive techniques such as tumor ablation by patients and healthcare professionals is expected to drive the growth of the market.
Technological advancements, particularly in the field of robotics-assisted tumor ablation, have emerged as a major driver for the growth of the tumor ablation market. This innovative approach to cancer treatment combines the precision of robotics with the effectiveness of tumor ablation techniques, such as radiofrequency or microwave ablation. Robotic systems, equipped with advanced imaging and navigation capabilities, enable surgeons to precisely target and destroy cancerous tissue with minimal damage to surrounding healthy cells. This not only enhances the overall effectiveness of tumor ablation but also significantly reduces the risk of complications and side effects associated with traditional surgical procedures.
However, side-effects associated with ablation treatment and stringent government regulations are the major restraints for the market growth. There is the risk of infection, bleeding, or damage to surrounding healthy tissues. These complications can lead to extended hospital stays and increased healthcare costs. Additionally, tumor ablation may not be suitable for all cancer types or stages. Its effectiveness tends to vary, and it may not be as successful in treating larger or deeply located tumors.
Moreover, the surge in research and development activities within the field of tumor ablation presents a pivotal growth opportunity for the tumor ablation market. Researchers and healthcare institutions are increasingly focusing on refining existing ablation technologies and exploring innovative approaches. This emphasis on research and development is primarily driven by the ever-growing incidence of cancer and the quest for improved patient outcomes.
Segmental Overview
The tumor ablation market share is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
By Technology
The tumor ablation market is categorized into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. The others segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period. This is attributed to the adoption of laser ablation and high intensity focused ultrasound technology owing to its high accuracy. However, the microwave ablation segment is expected to register fastest CAGR owing to owing to its remarkable efficacy in treating various types of tumors. Unlike some other ablation methods, such as radiofrequency or cryoablation, microwave ablation offers distinct advantages, including its ability to create larger ablation zones and generate higher temperatures, which results in more effective tumor destruction.
By Treatment
The market is categorized into surgical ablation, laparoscopic ablation, and percutaneous ablation. The surgical ablation segment dominated the global market in 2022 and is anticipated to continue this trend during the forecast period due to prevalence of cancer and advancements in tumor ablation technology.
By Application
The market is categorized into kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer and bone cancer. The liver cancer segment dominated the market in 2022, owing to high prevalence of liver cancer globally. However, the kidney cancer segment is expected to register the fastest CAGR owing to high adoption of tumor ablation technique to treat kidney cancer.
By Region
The tumor ablation market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. On the basis of region, North America had the highest market share in 2022, owing to presence of major key players, and rise in prevalence of cancer. However, Asia-Pacific is expected to exhibit the fastest growth during the tumor ablation market forecast, owing to a rise in geriatric population, increase in demand for minimally invasive treatment, and rise in the number of hospitals & clinics.
Competition Analysis
Competitive analysis and profiles of the major players in the tumor ablation industry, such as Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra Life Sciences, AngioDynamics, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation. Major players in the tumor ablation industry have adopted product development, product approval, acquisition, and partnership as key developmental strategies to improve the product portfolio and gain strong foothold in the tumor ablation market.
Recent Product Development in the Tumor Ablation Market
In July 2020, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for transbronchial microwave ablation technology using robotic-assisted bronchoscopy, which is currently under development.
Recent Product Approval in the Tumor Ablation Market
In July 2020, Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced today that it has received FDA clearance for a specific indication for neurosurgery for its CUSA Clarity. CUSA Clarity can be used safely and effectively in neurosurgery for the resection of tumors ranging from soft to firm consistencies, which include the removal of primary and secondary malignant, and benign brain and spinal tumors, including but not limited to meningiomas and gliomas.
Recent Acquisition in the Tumor Ablation Market
In October 2021, Bioventus LLC announced the completion of the acquisition of Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes.
Recent Partnership in the Tumor Ablation Market
In May 2023, AngioDynamics announced that it has formed a new partnership with Minimax Medical for the international distribution of its product portfolio. The partnership will include the distribution of Minimax Medical’s leading Radiofrequency Ablation System for tumors/nodules on an international level.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the tumor ablation market analysis from 2022 to 2032 to identify the prevailing tumor ablation market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the tumor ablation market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global tumor ablation market trends, key players, market segments, application areas, and market growth strategies.
Tumor Ablation Market Report Highlights
| Aspects | Details |
 Market Size By 2032 | USD 5 billion |
 Growth Rate | CAGR of 13.5% |
 Forecast period | 2022 - 2032 |
 Report Pages | 240 |
 By Technology |
|
 By Treatment |
|
 By Application |
|
 By Region |
|
 Key Market Players | Olympus Corporation, Integra LifeSciences Holdings Corporation, Boston Scientific Corporation, HealthTronics, Inc., Bioventus LLC, Medtronic plc, Johnson & Johnson, Smith & Nephew plc, ConMed Corporation, AngioDynamics, Inc. |
Analyst Review
According to CXOs of leading companies in the market, the growth of the tumor ablation market is attributed to factors such as increase in cases of different types of cancers such as breast, lung, kidney and liver, coupled with emergence of technologically advanced treatments for effective management of cancer conditions. The tumor ablation market garnered interest of healthcare & pharmaceutical and biotechnology companies, owing to high utilization of ablation technologies for effective cancer treatment. This leads to an increase in demand for minimally invasive treatments, which drives growth of the market. Laser ablation and high intensity focused ultrasound technologies are mostly preferred for destruction of target tumor cells, owing to its accuracy, efficiency, and safety related to brain, liver, and lung tumors. According to the National Cancer Institute, prostate cancer is second most common type of cancer in the U.S. The surgical ablation segment was the largest revenue contributor in 2022, owing to its various clinical applications in diagnosis of renal tumor, hepatic tumor, and malignant liver tumor.
Further, North America is expected to witness the highest growth, in terms of revenue, owing to rise in prevalence of cancer cases, presence of key players, increase in awareness regarding cancer treatment, and increase in geriatric population in the region. Europe was the second largest contributor to the market in 2022 and is expected to register the fastest CAGR during the forecast period, owing to emergence of standardized methods and technological advancements in ablation treatment, increase in cases of various cancers, and geriatric population. In addition, side-effects associated with tumor ablation such as abdominal pain, infection, and bleeding inside the body while performing treatment are anticipated to restrain the market growth during the forecast period.
Tumor ablation devices are innovative medical tools and techniques used in the treatment of tumors, particularly in cases where surgery is not a viable option or when patients seek minimally invasive alternatives.
Increase in prevalence of cancer and increase in demand for minimally invasive tumor ablation techniques.
Rise in research and development activities for tumor ablation is the major factors that are expected to create lucrative opportunities for the growth of the market.
Top companies such as Medtronic plc, Boston Scientific Corporation, Smith and Nephew PLC, Integra Life Sciences, AngioDynamics, HealthTronics, Inc, Bioventus (Misonix Inc), Johnson and Johnson, ConMed Corporation and Olympus Corporation held a high market position in 2022.
The total market value of the tumor ablation is $1413.85 million in 2022.
The forecast period for tumor ablation market is 2023 to 2032.
The base year is 2022 in tumor ablation market.
Surgical ablation segment dominated the global market in 2022 and expected to continue this trend throughout the forecast period.
Rise in research and development activities for tumor ablation is the major factors that are expected to create lucrative opportunities for the growth of the market.
Loading Table Of Content...
Loading Research Methodology...
